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The MATCH Study Results in the Context of Secondary
Stroke Prevention
Marc Fisher, MD; Antonio Davalos, MD, PhD
The performance of randomized clinical trials providesevidence-based medical information to clinicians and
impacts on day-to-day treatment decisions. Many secondary
stroke prevention trials over the past 4 decades have provided
much useful information concerning the efficacy or lack
thereof of different therapies for reducing recurrent stroke
risk. For platelet antiaggregants, placebo-controlled trials are
no longer justified and comparator trials evaluating drug
combinations in comparison to monotherapy are appropriate.
The MATCH trial evaluated the efficacy and safety of
combined clopidogrel–aspirin therapy to clopidogrel alone in
high-risk patients with completed stroke or transient ischemic
attack who also had 1 or more of 5 additional risk factors. The
combined endpoint of ischemic stroke, myocardial infarction,
vascular death, or recurrent hospitalization for an ischemic
event was used. The study demonstrated an insignificant
trend for greater efficacy with the combination therapy on the
primary endpoint, but a highly significant increased risk for
life-threatening bleeding side effects.
Because of the importance of this study, we asked for
critiques from both North American and non-North American
perspectives. Dr Caplan invokes a familiar theme that the
precise nature of the arterial lesion was not well-characterized
in MATCH, similar to the situation in other platelet anti-
aggregant trials and the recently reported Warfarin–Aspirin
Recurrent Stroke Study (WARRS). He additionally points out
that50% of the patients in MATCH were classified as small
vessel in subtype, a figure similar to the WARRS study. This
is a disproportionate number when compared with general
stroke registries that likely affected the power and generaliz-
ability of these trials. Dr Caplan concludes that comparing
clopidogrel–aspirin to clopidogrel alone and not aspirin alone
leaves unanswered questions concerning the effectiveness
and safety of the combination in comparison to the currently
most widely used platelet antiaggregant in cerebrovascular
patients, aspirin. Ongoing studies are addressing this issue.
Drs Amarenco and Donnan provide a different perspective
on the MATCH trial and its results. They emphasize that the
study population was skewed toward multiple risk factors
because of the requirement for high-risk patients and that
68% had diabetes mellitus, which is a very high percentage.
They also raise concerns about the substantial percentage of
small-vessel disease patients in the study and the impact on
outcome events. They conclude that the MATCH results for
a trend toward greater efficacy of the combination of clopi-
dogrel plus aspirin and the significant risk of life-threatening
bleeding can only be applied to a cerebrovascular population
similar to that included in the study. They support the
continuation of ongoing studies that are evaluating this
combination in comparison to aspirin or warfarin and suggest
that clinicians “exercise caution” in prescribing clopidogrel
plus aspirin to patients with diabetic cerebrovascular disease.
The critiques of the MATCH study provided by Dr
Caplan, and Drs Amarenco and Donnan are both insightful
and somewhat disparate in their conclusions. Until proven
no more risky than aspirin alone or the combination of
aspirin/extended-release dipyridamole, the combination of
clopidogrel/aspirin cannot, in our opinion, be recom-
mended for use in routine clinical practice for cerebrovas-
cular disease patients. An exception might be considered
for cerebrovascular disease patients undergoing a cardiac
procedure such as stenting/angioplasty in which the CURE
study suggests benefit, but in this setting the combination
of clopidogrel/aspirin should likely be used for months and
not indefinitely. The efficacy and safety of clopidogrel/
aspirin in cerebrovascular disease patients need to be
explored in additional clinical trials and some are already
ongoing. However, the data and safety-monitoring boards
of such trials need to be particularly vigilant concerning
life-threatening bleeding side effects to avoid continuing to
accrue patients if a similar bleeding risk emerges as was
observed in the MATCH study.
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